Page 8 - பிரேசிலியன் ஆரோக்கியம் அமைச்சகம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

    Reuters Published: 14 May 2021 08:50 AM BdST Updated: 14 May 2021 08:50 AM BdST People walk along at a street, following the outbreak of the coronavirus disease, in Shanghai, China May 10, 2021. REUTERS Chinese biotech firm Kintor Pharmaceutical Limited saw its stock price jump by more than 20% the day after it announced on April 25 that it had completed the first patient enrolment and dosing in a late-stage US clinical trial of its experimental COVID-19 treatment. ); } It was the company s latest announcement about the progress of the drug, Proxalutamide. The Hong Kong-listed company s stock price has nearly quadrupled since March 1 as some analysts wrote about the big sales potential for a COVID-19 treatment. Kintor has seen its market capitalisation soar to HK$23.4 billion ($3 billion) from HK$6.6 billion ($850 million) on March 1.

United statesHong kongLucy luAlexandre cavalcantiRicardo zimermanZeid kayaliStephen ostroffCarlos wambierJair bolsonaroBrazilian health ministryBrazil health ministryInternational in hong kongSao paulo hcor research instituteDrug administrationBrown universityHong kong listed